TL;DR
- The $700 billion global food system is bifurcating: precision agriculture (hardware + software for existing farms) is generating 20%+ ROIC, while alternative protein companies (Beyond Meat, Oatly) have destroyed 90–98% of shareholder value since their peaks. The market is learning that selling efficiency to farmers is profitable; selling ideology to consumers is not.
- Deere & Company (DE) is the dominant platform play, combining autonomous tractors, See & Spray precision technology, and a recurring SaaS revenue stream through its Operations Center. At 16x NTM EBITDA, Deere trades at a discount to its technology content and switching-cost moat.
- Agricultural biologicals (microbial crop protection and biostimulants) are growing at 12–15% annually and represent a $25 billion market by 2028. Corteva Agriscience and FMC Corporation are the best-positioned public companies, with CRISPR crop editing adding a medium-term catalyst.
- Vertical farming and lab-grown meat remain economically unviable at scale. AppHarvest and AeroFarms both filed for bankruptcy in 2023. Energy costs of $2.40–4.80/kg for indoor produce make field-grown alternatives structurally unbeatable for most crop categories.
- Use DataToBrief to track precision ag adoption data, crop input pricing, and earnings transcripts from Deere, Corteva, and CNH — the data signals that drive agritech stock performance are buried in dealer channel checks and USDA filings that most investors overlook.
The $700 Billion Food System Split: Precision Ag vs. Alt-Protein
The global food and agriculture industry generates roughly $700 billion in annual revenue across equipment, crop inputs, food processing, and distribution. Over the past five years, investors poured capital into two distinct theses: precision agriculture (making existing farming more efficient) and alternative protein (replacing animal agriculture entirely). The market has now rendered its verdict. Precision agriculture works. Alternative protein, as currently constituted, does not.
The numbers are stark. Deere & Company, the dominant precision ag platform, has delivered a 28% total shareholder return CAGR since 2019 and generated $9.2 billion in free cash flow in fiscal 2025. Its ROIC has averaged 32% over the past five years. Meanwhile, Beyond Meat has burned through $1.8 billion in cumulative cash since its 2019 IPO and trades at a market cap below $300 million — less than its 2019 first-day closing market cap of $3.8 billion. Oatly, the Swedish oat milk company, has lost 94% of its value from its May 2021 IPO.
This is not a story about good ideas versus bad ideas. Both precision ag and alt-protein address real problems. The difference is unit economics. Precision agriculture sells measurable ROI to farmers — a $400,000 autonomous tractor that saves $60,000 annually in labor and input costs pays for itself in under seven years. Alternative protein asks consumers to pay a 2–3x premium for products that most people think taste worse than what they replace. One is a B2B efficiency sale with quantifiable payback. The other is a B2C behavioral change bet with no clear value proposition beyond ideology.
The contrarian angle: Beyond Meat's failure does not invalidate the plant-based thesis entirely. It invalidates the premium-priced, processed plant-based approach. Companies like Impossible Foods (private) are pivoting to price parity with conventional meat, and cultivated meat startups like Upside Foods are targeting foodservice where taste differences are masked by preparation. The next generation of alt-protein may succeed where this one failed — but that is a venture capital bet, not a public equity thesis.
Deere & Company: The Precision Agriculture Platform
Deere is not a tractor company. That framing has cost investors money for a decade. Deere is an agricultural technology platform that happens to deliver its software through hardware. The company's technology stack now includes GPS-guided auto-steer (90%+ penetration on new large tractors), See & Spray (computer vision that identifies weeds and applies herbicide only where needed, reducing chemical usage by 60–70%), ExactEmerge planters (variable-rate seeding at up to 10 mph), and autonomous tractors that can operate 24/7 without a human in the cab.
The financial model is evolving in Deere's favor. Historically, agricultural equipment was a cyclical business driven by crop prices and farm income. Deere still has cyclical exposure — its FY2025 revenue declined 16% year-over-year as the North American ag equipment cycle peaked — but the technology overlay is dampening cyclicality. Technology-enabled equipment carries 15–25% price premiums. The Operations Center software platform generates recurring revenue that does not fluctuate with equipment purchase cycles. And the data lock-in creates switching costs that rival enterprise SaaS: once a farmer has five years of field data, prescription maps, and yield analytics in Deere's ecosystem, migrating to a competitor means starting from scratch.
Autonomous Tractors: The Inflection Point
Deere launched its first fully autonomous tractor in 2022 and has been expanding availability through a phased commercial rollout. The autonomous 8R tractor can till 325 acres per day without an operator, working through the night and in conditions where human operators would stop. For a 5,000-acre corn farm spending $150,000 annually on seasonal labor, autonomy eliminates that cost entirely while increasing throughput by 30–40% (no breaks, no shift changes, no weather-related work stoppages).
The labor shortage angle is critical. The US farm labor force has declined 20% since 2006, and the average age of American farmers is 58. Autonomous equipment is not a luxury for large-scale operations — it is a necessity. Deere management has guided for 10% of its large tractor fleet to be autonomous-capable by 2030. We think that estimate is conservative; labor economics will force faster adoption. At a 15–20% price premium per unit and a recurring autonomy software subscription, this represents a $3–5 billion incremental annual revenue opportunity.
The Competitive Landscape: Who Wins in AgriTech
AgriTech spans equipment manufacturers, crop input companies, agricultural biologicals, and pure-play technology providers. The competitive dynamics differ markedly by segment.
Equipment Manufacturers
Deere, CNH Industrial (Case IH, New Holland), and AGCO (Fendt, Massey Ferguson) form an oligopoly in large agricultural equipment. Deere holds approximately 35% North American market share in large tractors and 50%+ in combines. CNH is the closest competitor at roughly 25% share. AGCO, while the smallest of the three in North America, dominates European markets through Fendt, which commands premium pricing and 28%+ operating margins in its ag segment.
The technology gap is widening. Deere spends approximately $2.1 billion annually on R&D (6% of revenue), versus $1.4 billion for CNH and $500 million for AGCO. That cumulative investment advantage, sustained over a decade, has given Deere a 3–5 year lead in autonomous driving, computer vision, and data analytics. CNH is responding through its Raven Industries acquisition ($2.1 billion in 2021) and has delivered competitive auto-steer products, but the integrated platform gap remains significant.
| Company | Ticker | Market Cap | NTM P/E | 5Y Avg ROIC | R&D % Rev | Key Edge |
|---|---|---|---|---|---|---|
| Deere & Company | DE | $120B | 18.5x | 32% | 6.0% | Autonomous, See & Spray, data platform |
| CNH Industrial | CNH | $18B | 9.5x | 14% | 4.2% | Raven acquisition, global distribution |
| AGCO Corporation | AGCO | $8B | 8.8x | 12% | 3.8% | Fendt premium brand, European dominance |
| Corteva Agriscience | CTVA | $42B | 20.5x | 10% | 8.1% | CRISPR crop editing, biologicals pipeline |
| FMC Corporation | FMC | $6B | 11.2x | 9% | 6.5% | Diamides franchise, biologicals growth |
Crop Inputs & Biologicals: The Quiet Growth Story
Agricultural biologicals — microbial-based crop protection, biostimulants, and bio-fertilizers — are the fastest-growing segment in crop inputs. The market reached approximately $15 billion in 2025 and is growing at 12–15% annually, driven by regulatory restrictions on synthetic chemicals, farmer demand for soil health preservation, and performance improvements in biological formulations that have closed the efficacy gap with traditional chemistry.
Corteva Agriscience is the most compelling pure-play. Spun off from DowDuPont in 2019, Corteva generates approximately $17 billion in annual revenue split between seed (60%) and crop protection (40%). The biologicals portfolio is still small at roughly $600 million in revenue, but it is growing at 20%+ annually and carries gross margins above 60% — significantly higher than the 45% margins on traditional synthetic chemistry. Corteva's CRISPR gene-editing pipeline adds a second growth vector: its edited waxy corn is already commercialized, and 15+ additional traits are in development targeting drought tolerance, nitrogen fixation, and disease resistance.
FMC Corporation offers a different angle. FMC's diamides insecticide franchise (Rynaxypyr) generates roughly $3 billion in annual revenue with patent protection through 2028 in most markets. The stock has underperformed over the past two years due to channel inventory destocking and a down-cycle in crop protection spending, but at 11x forward earnings FMC prices in minimal growth. If the crop protection cycle recovers in 2026–2027 as dealer inventories normalize, FMC offers 30–40% upside from current levels. Understanding these unit economics dynamics is essential for timing the entry.
CRISPR Crop Editing: The Regulatory Arbitrage
The USDA's 2023 SECURE Rule created a regulatory pathway for CRISPR-edited crops that avoids the 10–13 year approval timeline required for transgenic GMOs. Gene-edited crops that could have been produced through conventional breeding — essentially, edits that delete or modify existing genes rather than insert foreign DNA — can reach market in 3–5 years. This regulatory arbitrage is a game-changer. Corteva's pipeline includes edited soybeans with improved oil profiles, corn with enhanced drought tolerance, and wheat with reduced allergen content. Bayer, through its Crop Science division, is pursuing similar programs but is constrained by $16 billion in remaining Roundup litigation liabilities that limit R&D investment flexibility.
The Alt-Protein Graveyard: Lessons for Food-Tech Investors
Beyond Meat's trajectory is a masterclass in what happens when narrative overrides unit economics. At its July 2019 peak of $235 per share, Beyond Meat traded at 40x revenue with negative gross margins in several quarters. The thesis was simple: plant-based meat would capture 10–15% of the $1.4 trillion global meat market within a decade. That implied a $140–210 billion TAM. The stock traded as if 5% penetration were inevitable.
Reality intervened. US retail plant-based meat sales peaked at $1.5 billion in 2021 and have been flat to declining since. Repeat purchase rates collapsed — 70% of consumers who tried plant-based meat did not buy it a second time, according to Deloitte consumer survey data. Beyond Meat's revenue has declined for four consecutive years. Gross margins turned negative in 2022 and have not recovered. The company has $1.1 billion in long-term debt, $200 million in cash, and no clear path to profitability.
Oatly tells a similar story in plant-based dairy. The company grew revenue 50%+ annually from 2019 to 2022, but at the cost of worsening unit economics. Oatly's gross margin peaked at 30% in 2020 and declined to 22% by 2025 as manufacturing inefficiencies, commodity cost volatility, and competitive pressure from store-brand oat milk alternatives compressed pricing power. The lesson is transferable: consumer behavior change is the riskiest bet in food-tech. Selling efficiency to producers (precision ag) has a fundamentally different risk profile than selling ideology to consumers (alt-protein).
The one alt-protein company that may survive: Impossible Foods (private, last valued at $7 billion in 2022, likely worth $2–3 billion today) has pivoted from premium pricing to cost parity with conventional ground beef. If Impossible can achieve and sustain 30%+ gross margins at $5.99/lb retail pricing, it has a viable business. But viable is not the same as venture-scale returns for early investors who backed the company at a $7 billion valuation.
Vertical Farming & Controlled Environment: The Energy Problem
Vertical farming was supposed to revolutionize fresh produce. The pitch was compelling: grow leafy greens year-round in climate-controlled facilities near population centers, eliminating transportation costs, weather risk, and water waste. Over $5 billion in venture capital flowed into the sector between 2018 and 2023. Then physics reasserted itself.
The fundamental challenge is energy cost. Replacing sunlight with LED lighting requires 30–40 kWh per kilogram of produce. At $0.10/kWh, that is $3–4 per kilogram in electricity alone — more than the retail price of field-grown lettuce. AppHarvest, which raised $600 million to build controlled-environment greenhouses in Appalachia, filed for Chapter 11 in July 2023 with revenues of just $14 million and operating losses of $200 million. AeroFarms, which had raised $238 million and operated the world's largest indoor vertical farm in Newark, New Jersey, filed for bankruptcy in June 2023.
The vertical farming model works for one narrow category: high-value leafy greens and herbs in geographies with extreme climates (Middle East, Scandinavia) or limited arable land (Singapore, Japan). In those contexts, the premium for locally grown, pesticide-free produce justifies the energy cost. But this is a niche worth perhaps $2–3 billion globally — not the $50 billion market that venture pitches promised.
Investment Framework: Where to Allocate in Food & Agriculture
Our conviction-ranked framework for food-tech and agritech investing prioritizes businesses with demonstrated unit economics, recurring revenue characteristics, and structural tailwinds that do not depend on consumer behavior change.
Highest conviction: Deere & Company (DE). The autonomous agriculture platform with the widest moat, highest R&D spending, and most entrenched installed base. At 18.5x NTM earnings through a cyclical trough, the risk-reward is skewed to the upside. We see $550–600 fair value on a mid-cycle earnings normalization, versus approximately $420 today.
High conviction: Corteva Agriscience (CTVA). The biologicals and gene-editing growth engine within a stable seed and crop protection business. At 20.5x NTM earnings, Corteva is not cheap, but the 15–20% earnings growth embedded in the biologicals transition justifies the premium. The CRISPR pipeline is an unpriced option.
Contrarian value: FMC Corporation (FMC). Beaten down by the crop protection destocking cycle, FMC at 11x earnings prices in permanent value destruction. If the cycle normalizes — and crop protection cycles always normalize — there is meaningful upside from a low base.
Avoid: Beyond Meat (BYND), Oatly (OTLY), and any public company whose revenue model depends on consumer willingness to pay premium prices for inferior-tasting food substitutes. The TAM was a mirage.
Frequently Asked Questions
What is precision agriculture and why is it investable?
Precision agriculture uses GPS-guided machinery, remote sensing, soil analytics, and AI-driven decision support to optimize crop yields while minimizing input costs. The global precision ag market is projected to reach $16.5 billion by 2028, growing at roughly 13% CAGR from $9.5 billion in 2023. The investability stems from clear ROI: farmers deploying precision ag tools typically see 10-15% yield improvements and 15-20% input cost reductions within two years. Unlike alt-protein companies that require consumers to change behavior, precision ag sells efficiency gains to an existing customer base of 570 million farms globally. Deere & Company dominates the space with its See & Spray technology, autonomous tractors, and integrated operations platform that locks in recurring software revenue. The business model mirrors enterprise SaaS — high switching costs, recurring revenue, and expanding margins as the installed base grows.
Why have alternative protein stocks like Beyond Meat and Oatly collapsed?
Beyond Meat and Oatly represent a cautionary tale in food-tech investing. Beyond Meat traded at $235 per share in mid-2019 and sits below $5 in early 2026 — a 98% decline. Oatly IPO'd at roughly $17 in 2021 and trades near $1. The fundamental problem is unit economics: Beyond Meat's gross margin has hovered around 0-5% for six consecutive quarters, meaning the company barely covers its cost of goods sold before any operating expenses. The alt-protein thesis assumed rapid consumer adoption and manufacturing scale would drive margins toward 35-40%, similar to traditional packaged food. Instead, repeat purchase rates collapsed as novelty faded, grocery shelf space contracted, and consumers proved unwilling to pay 2-3x premiums for plant-based substitutes that taste worse than the real thing. The category was a TAM mirage — theoretical addressable market was enormous but actual willingness-to-pay was thin.
How does Deere & Company make money from precision agriculture?
Deere generates precision ag revenue through three channels: (1) premium-priced hardware — autonomous and semi-autonomous tractors, combines, and sprayers sell at 15-25% premiums over conventional equipment, contributing to Deere's 20%+ equipment operating margins; (2) technology subscription fees — the John Deere Operations Center, which manages farm data and prescriptions, generates recurring SaaS-like revenue estimated at $800 million annually and growing at 20%+; and (3) aftermarket lock-in — once a farm invests in Deere's precision ecosystem (GPS receivers, data layers, machine connectivity), switching to CNH or AGCO means abandoning years of accumulated field data and retraining operators. Deere has invested over $10 billion in technology acquisitions since 2017, including Blue River Technology (computer vision for weed detection) and Bear Flag Robotics (autonomous driving). The strategy mirrors what Microsoft did with Azure: use a dominant hardware installed base to cross-sell higher-margin software and services.
What role does CRISPR gene editing play in agricultural investment?
CRISPR-based crop editing represents a $4-6 billion addressable market by 2030, focused on developing crop varieties with higher yields, drought tolerance, disease resistance, and improved nutritional profiles — without the regulatory burden of traditional GMOs. The USDA ruled in 2023 that many CRISPR-edited crops do not require the same lengthy approval process as transgenic GMOs, dramatically shortening time-to-market from 10-13 years to 3-5 years. Corteva Agriscience is the leader here, with a CRISPR-edited waxy corn already commercialized and a pipeline of 15+ edited crop traits. Bayer Crop Science and BASF are also investing heavily. For investors, CRISPR ag is a medium-term catalyst (3-5 year commercialization cycles) rather than a near-term revenue driver. The purest public plays are Corteva, which has the broadest crop editing pipeline, and to a lesser extent Bayer, where the ag division is overshadowed by Roundup litigation liabilities.
Is vertical farming economically viable as an investment?
Vertical farming remains economically challenged for most crops. The core problem is energy cost: indoor growing requires 30-40 kWh of electricity per kilogram of produce, versus effectively zero for field-grown crops that use sunlight. At average US commercial electricity rates of $0.08-0.12 per kWh, energy alone costs $2.40-4.80 per kilogram before labor, nutrients, or depreciation. This makes vertical farming viable only for high-value, short-shelf-life crops like leafy greens, herbs, and microgreens where the value per kilogram justifies the energy input. AppHarvest, which attempted large-scale controlled-environment agriculture for tomatoes, filed for bankruptcy in 2023. AeroFarms, once the world's largest vertical farm operator, also filed Chapter 11 in 2023. The survivors — Plenty Unlimited (backed by SoftBank) and Bowery Farming — remain private and unprofitable. We view vertical farming as a technology with a viable niche but not a scalable investment thesis at current energy economics.
Track Agricultural Technology Trends with AI-Powered Research
AgriTech investment signals — precision ag adoption rates, crop input pricing cycles, USDA data releases, dealer channel inventory checks, and earnings transcripts from Deere, Corteva, CNH, and AGCO — are scattered across regulatory filings and industry reports that most generalist investors never see. DataToBrief synthesizes these signals automatically, giving you the information edge on the sectors where food meets technology.
This article is for informational purposes only and does not constitute investment advice. The opinions expressed are those of the authors and do not reflect the views of any affiliated organizations. Past performance is not indicative of future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions. The authors may hold positions in securities mentioned in this article.